1. Home
  2. List
Reference Patent

Reference - List

  • 14 Hits
  • Search Condition : Filter (MeSH = Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*)
Species Resource Title
Human and Animal Cells WEHI-3(RCB0035) , Ba/F3(RCB0805) Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
Human and Animal Cells K562 Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Human and Animal Cells OP9(RCB1124) Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence.
Human and Animal Cells K562 Improved FRET Biosensor for the Measurement of BCR-ABL Activity in Chronic Myeloid Leukemia Cells.
Human and Animal Cells K562(RCB0027) Differentiation in chronic myelogenous leukemia cell K562 by spongean sesterterpene.
Human and Animal Cells K-562(RCB1635) Continuous Cytostatic Effects of BCR-ABL Tyrosine Kinase Inhibitors (TKIs) after Washout in Human Leukemic K562 Cells.
Human and Animal Cells K562(RCB0027) ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells.
Human and Animal Cells K562 Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia.
Human and Animal Cells Ba/F3(RCB0895) Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.
Human and Animal Cells THP-1(RCB1189) Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
Human and Animal Cells K562 Erythroid differentiation in K562 chronic myelogenous cells induced by crambescidin 800, a pentacyclic guanidine alkaloid.
Human and Animal Cells Effect of arsenic trioxide on different cell lines derived from chronic myeloid leukemia.
Human and Animal Cells KU812(RCB0495) , K562 Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Mice RBRC02339 NADPH oxidases as therapeutic targets in chronic myelogenous leukemia.